12:00 AM
Feb 10, 2003
 |  BioCentury  |  Product Development

Sifting the Iressa outcomes in Japan

Rates of interstitial lung disease in Japanese patients treated with AstraZeneca plc's Iressa are higher than in Iressa patients in other parts of the world. Last week, a group of experts assembled by the pharma company said it had found no direct relationship between Iressa and ILD. Instead, the difference appears to lie in the way the disease is diagnosed.

In response to the reports of ILD, two independent committees were formed - one by Japan and one by AZN. Japan's committee did not find a direct link between Iressa and ILD. In December, it recommended that Iressa patients be hospitalized for the first three to four weeks of treatment and be more closely supervised by a specialist,...

Read the full 574 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >